Joag S V, Liu Z Q, Stephens E B, Smith M S, Kumar A, Li Z, Wang C, Sheffer D, Jia F, Foresman L, Adany I, Lifson J, McClure H M, Narayan O
Marion Merrell Dow Laboratory of Viral Pathogenesis and Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
J Virol. 1998 Nov;72(11):9069-78. doi: 10.1128/JVI.72.11.9069-9078.1998.
The chimeric simian-human immunodeficiency virus SHIVKU-1, bearing the envelope of human immunodeficiency virus type 1 (HIV-1), causes fulminant infection with subtotal loss of CD4(+) T cells followed by development of AIDS in intravaginally inoculated macaques and thus provides a highly relevant model of sexually transmitted disease caused by HIV-1 in human beings. Previous studies using this SHIV model had shown that the vpu and nef genes were important in pathogenesis of the infection, and so we deleted portions of these genes to create two vaccines, DeltavpuDeltanefSHIV-4 (vaccine 1) and DeltavpuSHIVPPc (vaccine 2). Six adult macaques were immunized subcutaneously with vaccine 1, and six were immunized orally with vaccine 2. Both viruses caused infection in all inoculated animals, but whereas vaccine 1 virus caused only a nonproductive type of infection, vaccine 2 virus replicated productively but transiently for a 6- to 10-week period. Both groups were challenged 6 to 7 months later with pathogenic SHIVKU-1 by the intravaginal route. All four unvaccinated controls developed low CD4(+) T-cell counts (<200/microliter) and AIDS. The 12 vaccinated animals all became infected with SHIVKU-1, and two in group 1 developed a persistent productive infection followed by development of AIDS in one. The other 10 have maintained almost complete control over virus replication even though spliced viral RNA was detected in lymph nodes. This suppression of virus replication correlated with robust antiviral cell-mediated immune responses. This is the first demonstration of protection against virulent SHIV administered by the intravaginal route. This study supports the concept that sexually transmitted HIV disease can be prevented by parenteral or oral immunization.
嵌合型猿猴 - 人类免疫缺陷病毒SHIVKU - 1携带1型人类免疫缺陷病毒(HIV - 1)的包膜,经阴道接种猕猴后会引发暴发性感染,导致CD4(+) T细胞部分丧失,随后发展为艾滋病,因此为人类由HIV - 1引起的性传播疾病提供了一个高度相关的模型。此前使用该SHIV模型的研究表明,vpu和nef基因在感染的发病机制中很重要,所以我们删除了这些基因的部分片段以制备两种疫苗,即DeltavpuDeltanefSHIV - 4(疫苗1)和DeltavpuSHIVPPc(疫苗2)。6只成年猕猴皮下接种疫苗1,6只成年猕猴口服疫苗2。两种病毒在所有接种动物中均引发了感染,但疫苗1病毒仅引发了一种非增殖性感染类型,而疫苗2病毒在6至10周的时间内进行了有效但短暂的复制。两组动物在6至7个月后经阴道途径用致病性SHIVKU - 1进行攻击。所有4只未接种疫苗的对照动物的CD4(+) T细胞计数均降低(<200/微升)并发展为艾滋病。12只接种疫苗的动物均感染了SHIVKU - 1,第1组中有2只动物发展为持续性增殖性感染,其中1只随后发展为艾滋病。其他10只动物即使在淋巴结中检测到剪接的病毒RNA,仍对病毒复制保持了几乎完全的控制。这种对病毒复制的抑制与强大的抗病毒细胞介导免疫反应相关。这是首次证明经阴道途径接种可预防强毒性SHIV。本研究支持通过胃肠外或口服免疫可预防性传播HIV疾病这一概念。